Loading...
PEAR.Q logo

Pear Therapeutics, Inc.OTCPK:PEAR.Q Aktienübersicht

Marktkapitalisierung US$142.0
Aktienkurs
n/a
1Y-100.0%
7D0%
1D0%
Wert des Portfolios
​
Siehe

Pear Therapeutics, Inc.

OTCPK:PEAR.Q Lagerbericht

Marktkapitalisierung: US$142.0

Pear Therapeutics (PEAR.Q) Aktienübersicht

Pear Therapeutics, Inc. ist ein kommerzielles Gesundheitsunternehmen, das in den Vereinigten Staaten softwarebasierte Arzneimittel entwickelt und vertreibt. Mehr Details

PEAR.Q grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung2/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit3/6
Dividenden0/6

Belohnungen

Der Umsatz stieg im vergangenen Jahr um 201.7%

Risikoanalyse

Hat keine nennenswerte Marktkapitalisierung ($142)

Aktien sind hochgradig illiquide

Die letzten Finanzberichte sind mehr als ein Jahr alt


PEAR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW474,966 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
474,966 investors already sharing narratives
View all narratives

Pear Therapeutics, Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Pear Therapeutics
Historische Aktienkurse
Aktueller AktienkursUS$0.000001
52-Wochen-HochUS$0.02
52-Wochen-TiefUS$0.000001
Beta8.21
1 Monat Veränderung0%
3 Monate Veränderung-99.00%
1 Jahr Veränderung-99.97%
3 Jahre Veränderung-100.00%
5 Jahre Veränderungn/a
Veränderung seit IPO-100.00%

Aktuelle Nachrichten und Updates

Analyseartikel • Apr 17

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Pear Therapeutics, Inc. ( NASDAQ:PEAR ) shareholders that were waiting for something to happen have been dealt a blow...

Recent updates

Analyseartikel • Apr 17

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Pear Therapeutics, Inc. ( NASDAQ:PEAR ) shareholders that were waiting for something to happen have been dealt a blow...
Seeking Alpha • Aug 18

Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue

Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indicates Pear is still annualising $12 million in revenue. They've laid off 9% of the workforce and operating expenses are down, and the focus is now mostly on the current line-up. Revenue guidance falls below our expectations at $15 million for 2022, so we're a little less convinced now since a venture is always a race against time. Published on the Value Lab 15/8/22 Pear Therapeutics (PEAR) is by far one of our worst performing ideas having been decimated in the SPAC boom. We quite agreed with the initial valuation given the blue skies in the markets and the treatment areas being so prevalent, but the markets, likely concerned also with reflexivity, were having none of it, thus a 80% decline. Now they've reported their Q2 results in their first year as a public company. From an execution point of view, we like what we see, but we're becoming aware of sluggishness in the realisation of agreements with payors, and since they are racing against time, despite the superb value add of the company to the health system and the substantial scope for value capture, we have our worries. Q2 Comments Let's start with the most important thing for any venture which is revenue. Q2 revenue was $3.3 million, 20% growth QoQ and 175% YoY, although the latter says nothing. This is annualising at around $12 million annually, and the guidance is for $15 million annually with the expectation of further QoQ growth. Major wins with payors came in with prescriptions rising quickly to over 10k, and ASPs at over $1.3k. While revenue growth is good, it takes a while for health systems to add Pear products to their coverage list, so despite the good uptake, accelerating any faster is not very doable. The leads take a good while to convert. Therefore, it can be said that the current revenue growth falling below our hopes is mostly a timing issue, where interest has yet to be realised into payor agreements, but the problem with a venture is that timing is everything. The company has about $100 million in cash and cash equivalents to last them into the following quarters. The company previously guided to 2023 being the next year where dilution will occur, but hopefully cost controls have somewhat pushed that out to mitigate a slower than hoped revenue trajectory. Pear has laid off 9% of its workforce, meaning a couple dozen people. Expenses have actually fallen by a couple of percent QoQ, which is great in light of the growing revenue, and these expenses are expected to continue to fall QoQ. But it is coming at a cost. Currently the Somryst and the reSET products are the ones that are getting coverage, the former for insomnia and related conditions and the latter being for substance abuse. Now with the cost cuts, the management is saying definitively that it is going to put work on its pipeline on the backburner. In addition to reducing our workforce, we substantially reduced work on pipeline candidates, discovery programs, business development, and our dual platforms. We didn't stop there. We also narrowed our commercial efforts to focus our resources on areas of highest coverage density, while de-prioritizing longer-term opportunities for the time being. As a result of the restructuring, we expect to reduce our operating expenses by approximately $28 million over 18 months. We expect to spend less in Q3 than we did in Q2, and we expect to spend less in Q4 than we did in Q3. Corey McCann, CEO of PEAR
Seeking Alpha • Aug 03

Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic

Pear Therapeutics' (NASDAQ:PEAR) opioid use disorder prescription digital therapeutic will be provided to Core Behavioral Health centers in the Tampa Bay, Fla., area. Cove will offer the reSET-O product in English and Spanish. reSET-O is a prescription cognitive behavioral therapy that is used as an adjunct to outpatient treatment. In June, a study showed that use of reSET-O led to a reduction in inpatient stays.
Seeking Alpha • May 21

Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction

Fulfilment rates are growing relative to last quarter, and so are prescriptions. Government traction is becoming more evident as states mandate coverage of Pear products for all resident Medicaid members, and payment rates should rise on account of that. As a digital company, they are pushing their own dashboard which seems to be picking up traction and creates some leverage potential for economies of scale and scope. ASPs are higher than we modeled still but will decline as rebates bring net prices down, but this would be concomitant with larger contracts and a good thing. Still early days, so who knows how long it will go, but the current cash position let us see till 2023 before more dilution.
Seeking Alpha • Apr 04

Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets

Pear delivered well for the FY despite only being a post-revenue company for part of it. Covered lives are developing fast, and prescription numbers have just started to ramp. 2022 will be a full year of performance, and the company is guiding to sharp increases in prescriptions. Fulfillment metrics look good, meaning that on the patient side things look good, so it's all about pushing with physicians now. Pear is too young to make precise estimates, but based on management statements, cash burn shouldn't deplete cash reserves till mid-2023 by which time we hope to see scaling.
Seeking Alpha • Jan 10

Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy

Pear is a category creator of Digital Therapeutics (DTx), which means its applications are reimbursed at phenomenal rates by payors and other benefit providers. The addressable market in the US alone is massive with Pear's treatment areas, and Pear is first out the gate. They have already achieved excellent R&D results on a small cost-base, and a digital pharma model will likely have inherently strong economics. Risks are primarily to do with educating the market, which also paves the way for competitors. Still, we are happy with the valuation given the intersection of digital health and telemedicine, two areas which have already proven quite revolutionary.

Aktionärsrenditen

PEAR.QUS Healthcare ServicesUS Markt
7D0%4.7%0.6%
1Y-100.0%-21.5%20.1%

Rendite im Vergleich zur Industrie: PEAR.Q unter dem Niveau der Branche US Healthcare Services , die im vergangenen Jahr eine Rendite von -21.5% erzielte.

Rendite vs. Markt: PEAR.Q hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.1 erzielte.

Preisvolatilität

Is PEAR.Q's price volatile compared to industry and market?
PEAR.Q volatility
PEAR.Q Average Weekly Movementn/a
Healthcare Services Industry Average Movement10.1%
Market Average Movement7.1%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: Der Aktienkurs von PEAR.Q war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von PEAR.Q im vergangenen Jahr zu bestimmen.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
2013200n/apeartherapeutics.com

Pear Therapeutics, Inc. ist ein im kommerziellen Stadium befindliches Gesundheitsunternehmen, das softwarebasierte Arzneimittel in den Vereinigten Staaten entwickelt und vertreibt. Die kommerziellen Produkte des Unternehmens sind reSET zur Behandlung von Störungen des Substanzkonsums im Zusammenhang mit Alkohol, Cannabis, Kokain und Stimulanzien, reSET-O zur Behandlung von Störungen des Opioidkonsums in Kombination mit Buprenorphin und Somryst, eine softwarebasierte Behandlung für chronische Schlaflosigkeit. Das Unternehmen entwickelt außerdem eine Pipeline von Produktkandidaten, die sich auf Psychiatrie, Neurologie und therapeutische Bereiche außerhalb des zentralen Nervensystems, wie Gastroenterologie, Kardiologie und Onkologie, konzentrieren.

Pear Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Pear Therapeutics im Vergleich zum Marktanteil des Unternehmens?
PEAR.Q grundlegende Statistiken
MarktanteilUS$142.00
Gewinn(TTM)-US$75.49m
Umsatz(TTM)US$12.69m
0.0x
Kurs-Umsatz-Verhältnis
0.0x
Kurs-Gewinn-Verhältnis

Ist PEAR.Q zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
PEAR.Q Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$12.69m
Kosten der EinnahmenUS$7.39m
BruttogewinnUS$5.30m
Sonstige AusgabenUS$80.79m
Gewinn-US$75.49m

Zuletzt gemeldete Gewinne

Dec 31, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-0.53
Bruttomarge41.75%
Nettogewinnspanne-594.70%
Schulden/Eigenkapital-Verhältnis89.7%

Wie hat sich PEAR.Q auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2024/05/27 04:29
Aktienkurs zum Tagesende2024/05/27 00:00
Gewinne2022/12/31
Jährliche Einnahmen2022/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Pear Therapeutics, Inc. wird von 6 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Michael ChernyBofA Global Research
Michael GormanBTIG
Marie ThibaultBTIG